Metagenomic studies have revealed a complex relationship between the microbiome and cancer. For example, certain bacteria such as Helicobacter pylori are known to be associated with stomach cancer, while the presence of Fusobacterium nucleatum has been linked to colorectal cancer. Additionally, the gut microbiome has been found to influence the effectiveness of immune checkpoint inhibitors, a type of cancer immunotherapy. These findings highlight the potential of targeting the microbiome for cancer prevention and treatment.
